Pre-made Runimotamab benchmark antibody ( Bispecific mAb, anti-ERBB2/HER2;CD3E therapeutic antibody, Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Runimotamab biosimilar, Bispecific mAb, Anti-ERBB2/HER2;CD3E Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-500-1mg	1mg	Inquiry
GMP-Bios-ab-500-10mg	10mg	Inquiry
GMP-Bios-ab-500-100mg	100mg	Inquiry
GMP-Bios-ab-500-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Runimotamab biosimilar, Bispecific mAb, Anti-ERBB2/HER2;CD3E Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;T3E/TCRE/IMD18 therapeutic antibody
INN Name	Runimotamab
Target	HER2;CD3E
Format	Bispecific mAb
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	IgG1;G1
VD LC	Kappa;Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Active
100% SI Structure	1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD;None
99% SI Structure	1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC;None
95-98% SI Structure	5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL;None
Year Proposed	2020
Year Recommended	na
Companies	Genentech
Conditions Approved	na
Conditions Active	Solid tumours
Conditions Discontinued	na
Development Tech	na